Drugs /

bemarituzumab

Back to Drugs List

Overview

NCI Definition [1]:
A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, the anti-FGFR2 antibody FPA144 specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC.

Clinical Trials

View Clinical Trials for bemarituzumab

Bemarituzumab has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating bemarituzumab, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).

ERBB2 Amplification, FGFR2 Amplification, and FGFR2 Expression are the most frequent biomarker inclusion criteria for bemarituzumab clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and gastric carcinoma are the most common diseases being investigated in bemarituzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bemarituzumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Bemarituzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bemarituzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
fpa144, anti-fgfr2 monoclonal antibody fpa144, bemarituzumab
Drug Target(s) [2]:
FGFR2
NCIT ID [1]:
C120040

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.